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Extended releaseAbstract The present study deals with the inﬂuence of hydroxypropylmethylcellulose 4000 in the
protection of Piroxicam polymorphs which could appear during the processes of formulation of
extended release tablets.
The physico-chemical tests and the dissolution proﬁles of polymorphs and tablets showed that
the metolose incorporated in the tablets at a rate equivalent to 5% could possibly act doubly; ini-
tially by protecting the piroxicam polymorphism transition (form II) during compression, then
modulating its in vitro release (extended release).
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The polymorphism of the Piroxicam was largely studied in the
30 last years. Indeed, the ﬁrst report on the polymorphism of
the Piroxicam was published in 1982 (Mihali´c et al., 1982). It
proves that two polymorphic modiﬁcations assigned as cubicand needle and a monohydrate form, obtained by crystalliza-
tion in various solvents, were known at that time.
In fact, former researches showed that the crystallization
of the Piroxicam melted in a thermal cell of analysis DTA
led to three modiﬁcations indicated by I, II and III
(Kuhnert-Brandsta¨tter and Vo¨llenklee, 1985). Some studies
showed that only modiﬁcation I (cubic) is physically stable
in a solid state to the thermal and mechanical stress (Vreˆcer
et al., 1991; Ghan and Lalla, 1992). Moreover, a study
carried out in 1997 (Shakhtshneider, 1997) showed that the
inﬂuence of a mechanical stress can generate the amorphiza-
tion of the Piroxicam.
Many other studies have been reported dealing with the
characterization of physicochemical properties of Piroxicam
(Ivashchenko et al., 2003; Sheth et al., 2004; Suarez-Kurtz,
Figure 1 DSC curves representing the four Piroxicam polymor-
phic forms. (a: form 1, b: form 2, c: form 3, d: monohydrate form.)
Table 1 Polymorphic forms of the Piroxicam.
Form Solvent Crystallization
kinetics
I Benzylic alcohol Slow
II Ethanol Slow
III Ethanol Rapid
IV Ethanol Slow (release)
Table 2 Tablet formula.
Raw materials Conventional
tablet (%)
Extended
tablet (%)
Piroxicam 04 04
CMC viva pure 101 13 13
HPC 06 –
HPMC 4000 – 05
Monohydrate lactose 77 78
S1244 A. Merah et al.2005; Tantishaiyakul et al., 2008, 2009; Pieszczek and
Jachowicz, 2010).
Aiming to study the role of the hydroxypropylmethylcellu-
lose 4000 in the protection of polymorphs of the Piroxicam ex-
tended release tablets, we proceeded as follows:
1. Initially, we prepared different Piroxicam polymorphs by
varying the nature of solvent and the kinetics of crystalliza-
tion, then we characterized the polymorphs obtained by
various analysis techniques namely: differential calorimet-
ric analysis (ACD), diffraction of X-rays (DRX), infra-
red spectroscopy (IR), and the solubility test and ﬁnally
we studied the proﬁle of dissolution of Piroxicam
polymorphs
2. Secondly and in order to test the effect of compression on
Piroxicam polymorphism, we formulated, with different
polymorphs of the selected active principle, the conven-
tional tablets which were characterized by the DRX and
studied considering the dissolution kinetics.
3. Finally, we formulated, with different Piroxicam poly-
morphs, tablets with extended release using the hydroxy-
propylmethylcellulose 4000, and then we followed the
dissolution kinetics of the Piroxicam based on these forms
after characterization with the DRX. The hydroxypropylm-
ethylcellulose can act doubly: initially by protecting the
transition of Piroxicam polymorphism when it undergoes
the compression stress, then by modulating the in vitro
release of the active principle.
2. Materials and methods
2.1. Materials
- Piroxicam: active principle; raw material Pﬁzer, (batch
0414890001).
- Pure microcrystalline cellulose viva: type 101, hydroxypro-
pylcellulose FG-CAS Aldrich.
- Lactose monohydrate Merck and Magnesium Stearate:
compression additives.- Hydroxypropylmethylcellulose HPMC 4000; Metolose 90
HS 4000 SR: Additive of the extended forms.
Role of hydroxypropylmethylcellulose (HPMC 4000) in the protection of the polymorphs of Piroxicam S12452.2. Preparation of polymorphs
It should be remembered that Piroxicam exists in several poly-
morphic forms:
- Form I, most stable
- Forms II and III, unstable
- Finally in the monohydrate form of yellow color.
For the realization of this work we carried out our tests
using a sample of active principle equivalent to 500 mg and
we prepared different polymorphs by varying the nature of em-
ployed solvent and the kinetics of crystallization as illustrated
in Table 1.
In fact, the polymorphic forms are obtained according to
the following method:
- Form I (cubic) by crystallization at ambient temperature of
a saturated solution in benzylic alcohol,
- Form II (needle) by crystallization at ambient temperature
of a saturated solution in ethanol,
- Form III by cooling with dry ice a saturated solution in
ethanol,
- Hydrate form by release of a saturated solution in ethanol.
2.3. Preparation of the tablets
In the present study, we prepared tablets with conventional re-
lease and tablets with extended release containing Piroxicam
(weight of the tablet: 400 mg). The Piroxicam is incorporated
at a rate of 4% (16 mg). This amount was selected for solubil-
ity and linearity reasons of the calibration curve (16 mg/l). The
selected formulas are mentioned in Table 2.
We prepared, for each polymorph, three compressed con-
ventional tablets and three with extended release by means
of a manual hydraulic press (press of standard workshopFigure 2 X-ray diffractogramPRMB, power 8 tons) with a compressive force of 20 kN, then
we studied the dissolution proﬁle of the Piroxicam from the
prepared tablets.
2.4. Characterization of the polymorphs
2.4.1. Differential calorimetric analysis
The differential calorimetric analysis (DSC) is carried out by
means of an apparatus of differential thermal analysis DSC6
Perkin Elmer calibrated with an indium/zinc standard and
controlled by the Pyris software.
For each polymorph, the test sample was approximately
3 mg. The sample is placed in an aluminum capsule then ex-
posed to a heating kinetics of 30–250 C, at a speed of
10 C/min.
2.4.2. X-ray diffraction
For the analysis of the crystalline structure of different Pirox-
icam polymorphs, we operated as follows: The sample to be
analyzed is crushed delicately in a mortar, then spread out over
a sample holder blade of glass then placed in the diffractome-
ter and exposed to X-rays.
The diffractometer used for the analysis is Philips type
[monochromatic irradiation Cua (0.15405 nm), the diffraction
angle 2h= (4–36), the voltage is 20 kV and the current inten-
sity is 40 mA].
The recording was carried out on 20 acquisitions and the re-
sults were treated using the software of processing data
GONIO.
2.4.3. Infra-red spectroscopy
The analysis of the powders of different polymorphs by infra-
red spectroscopy is carried out according to the following
protocol:
First the pellets are prepared by mixing approximately 3 mg
of polymorph to be analyzed with potassium bromide, and
then they are compressed under vacuum using a pellet pressof Piroxicam polymorphs.
Figure 3 Infra-red spectra of the four Piroxicam polymorphic
forms. (a: form 1, b: form 2, c: form 3, d: monohydrate form.)
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Figure 4 Dissolution proﬁles of forms 1, 2 and 3.
S1246 A. Merah et al.with a force of 10 tons. Once the pellet is made, it is introduced
into a Perkin Elmer standard 983G Infra-red
spectrophotometer.2.4.4. Solubility
The solubility test is carried out according to the method in
USP 30-nf 25 with revolving pallet under the following operat-
ing conditions:
- Test sample: 200 mg
- Test medium: 900 ml (pH = 1.2)
- Test temperature: 25 C and 37 C
- Stirring speed: 50 tours/min
It is worth noting that, the tests were carried out at 25 C
and 37 C in order to study the effect of the temperature in-
crease on the solubility of the polymorphs. The expressed re-
sult is the average of three tests.
At last, the optical densities were read on a UV–VISIBLE
Shimadzu UV-1601 spectrophotometer at the wavelength
k= 335 Nm.
It should be noted that the concentrations obtained after
the test of solubility were taken as solubility of forms 1, 2
and 3.
2.4.5. Dissolution kinetics
The dissolution kinetics is carried out according to the method
described in the USP 30 NF25.
The test is automated and controlled by a microcomputer
using WINASPECT software. The results are expressed as a
percentage of dissolved active principle.
Initially the dissolution tests of the three polymorphs of the
Piroxicam (forms 1, 2 and 3) are realized, according to follow-
ing operating conditions:
- Test sample 16 mg
- Test medium: 900 ml (pH = 1.2)
- Test temperature: 37 C
- Stirring speed: 50 tours/min
2.5. Control of tablets
2.5.1. X-rays diffraction of the tablets
We operated under to the same operating conditions as the
polymorphs. In fact, the tablets formulated with the different
polymorphs are initially crushed in a mortar, then spread
Table 3 Solubility of Piroxicam polymorphs at the temper-
atures 25 C and 37 C.
Polymorphs Solubility at 25 C
(mg/l)
Solubility at 37 C
(mg/l)
Form 1 176.75 185.71
Form 2 184.67 189.49
Form 3 158.50 158.84
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Figure 5 Diagram of X-ray diffraction of conventional tablets (form 1 of Piroxicam).
Role of hydroxypropylmethylcellulose (HPMC 4000) in the protection of the polymorphs of Piroxicam S1247out over a glass blade sample holder then placed in the
diffractometer.
2.5.2. In-vitro dissolution
We studied the dissolution proﬁles of tablets under the same
operating conditions as the polymorphs (according to the
method described in USP 30 NF25).Figure 6 Diagram of X-ray diffraction of co3. Results and discussion
3.1. Polymorphs
3.1.1. Differential calorimetric analysis
The differential calorimetric analysis shows for the four Pirox-
icam polymorphs: forms 1, 2, 3 and the monohydrate form, the
respective melting points: 202.40 C, 199.37 C, unstable and
203.40 C.
These results reveal that form 2 presents the lowest melting
point and appears on curve DSC as a shoulder point just after
its melting point. This could be due to the presence of two crys-
talline species in the sample which show a slight difference in
melting point.
In addition, the monohydrate form displays a dehydration
peak around 131.61 C.nventional tablets (form 2 of Piroxicam).
S1248 A. Merah et al.It is signiﬁcant to note that the form 3 is unstable and is
converted before its fusion, which is clearly illustrated on curve
DSC by the appearance of a small endothermic peak around
195.59 C (Fig. 1).
3.1.2. X-ray diffraction
The results of the diffractogram display the following angles
for the four polymorphic forms of the Piroxicam.
Form 1: 8.56; 11.64; 12.44; 14.44; 17.64; 21.64; 26.72; 27.32;
27.72.
Form2: 8.92; 14.96; 15.28; 15.52; 15.68; 17; 96; 19.56; 23.20;
25.32.
Form 3: 8.64; 8.92; 12.36; 12.88; 17.56; 18.16; 18.60; 25.04;
28.24; 29.24.
Monohydrate form: 11.84; 15.28; 18.32; 18.96; 19.44; 21.32;
26.16; 28.12.0
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Figure 7 Diagram of X-ray diffraction of co
Figure 8 X-rays diffraction diagram of extendThese results highlight the similarity between the diffraction
diagrams of the four crystalline forms of the Piroxicam and
those reported by Rasetti-Escargueil and Grange´ (2005). (see
Fig. 2).3.1.3. Infra-red spectroscopy
The infra-red spectroscopy seems to be very useful for the
characterization of the polymorphism of the Piroxicam. The
infra-red spectra of forms 1 and 2 (Fig. 3) are practically iden-
tical to those published by Mihali´c et al. (1982) and Vreˆcer
et al. (1991).
It is worth to note that the principal differences in the infra-
red spectra of Piroxicam polymorphs are observed between
3300 cm1 and 3400 cm1, corresponding to the vibrations of
the amide function N–H–C‚O.20 22 24 26 28 30 32 34 36
e 2theta 
pirocomp3
nventional tablets (form 3 of Piroxicam).
ed release tablets (form 1 of the Piroxicam).
Role of hydroxypropylmethylcellulose (HPMC 4000) in the protection of the polymorphs of Piroxicam S1249The infra-red spectra show the absorption peaks of the
amide function at 3337 cm1 and 3392 cm1 for forms 1 and
2, respectively.
The infra-red spectrum of form 3 shows a double peak for
the amide function located at 3341 cm1 and 3392 cm1.
The infra-red spectrum of the monohydrate form presents
notable differences compared to the other Piroxicam polymor-
phic forms. Indeed the peaks corresponding to the amide func-
tion are located at 3099 cm1 and 3452 cm1.
3.1.4. Solubility
The results mentioned in Table 3 show an increase in the sol-
ubility of the three crystalline forms of Piroxicam with increas-
ing temperature.0
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Figure 9 X-rays diffraction diagram of extend
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Figure 10 X-rays diffraction diagram of extendThese results are in contrast with those published by
Kozjek et al. (1985), which showed a reduction in the solubility
of form 2 with increasing temperature.
Indeed, our results show that form 2 shows a great solubil-
ity compared to the other forms. This is explained by the fact
that it has the minimum melting point. Once in contact with
the dissolution medium it dissolves easily. These results are
comparable with those reported in the literature (Vreˆcer
et al., 2003).
3.1.5. Dissolution proﬁles
The dissolution proﬁles of Piroxicam polymorphs (Fig. 4),
show that the most soluble form (form 2), displays a fast dis-
solution kinetics compared to the other two forms. In addition,20 22 24 26 28 30 32 34 36
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Figure 11 Dissolution proﬁles of tablets with conventional
release (forms 1, 2 and 3).
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Figure 12 Dissolution proﬁles of tablets with extended release
(forms 1, 2 and 3).
S1250 A. Merah et al.it should be noted that 75% of Piroxicam forms 1, 2 and 3 are
dissolved in 168 min, 40 min and 288 min, respectively.
These results are in agreement with those published in Cav-
allari et al. (2002) and Vreˆcer et al. (2003) and conﬁrm the re-
sults of the solubility study.
3.2. Tablets
3.2.1. X-ray diffraction of tablets with conventional release
The X-ray diffraction diagrams of the conventional tablets for-
mulated with the different Piroxicam polymorphs (Figs. 5–7)
show that after compression, the diffraction peaks are pre-
served for the tablets formulated with polymorphs 1 and 2
(Figs. 5 and 6), on the other hand for the tablets formulated
with polymorphs 3 (Fig. 7), we note the disappearance of the
peaks characterizing form 3. This could be possibly explained
by an amorphization of form 3. This phenomenon is reported
by Shakhtshneider (1997).
Also, it should be speciﬁed that to better visualize the poly-
morphic transformations with X-ray diffraction, the Piroxicam
was introduced at 10%.
3.2.2. X-ray diffraction of tablets with extended release
The X-ray diffraction diagrams of tablets with extended re-
lease formulated with the different Piroxicam polymorphs
(Figs. 8–10) show that after compression the diffraction peaks
are preserved for all the tablets.
These results could be in agreement with those found by
Andrea et al. (2004), which clearly mention the role of the
HPMC in the protection of the recrystallization of the amor-
phous indometacin and the dehydration of monohydrate the-
ophylline during compression.
3.2.3. Dissolution proﬁles of tablets with conventional release
Dissolution proﬁles of tablets with conventional release (forms
1, 2 and 3) (Fig. 11) show that 75% of Piroxicam with forms 1,
2 and 3 are dissolved in 120 min, 208 min and 88 min,
respectively.
According to these results and compared to the dissolution
proﬁles of pure polymorphs where the dissolution kinetics fol-
lows the order; accelerated for form 2, then form 1 then form 3
(Fig. 4), we note that after Piroxicam compression (forms 1, 2
and 3), the dissolution results are reversed. Indeed, the tablets
(form 2) show the slowest kinetics and it is rather the tablets
formulated with polymorph 3 which express the fastest disso-
lution kinetics.
These observations can be explained by the fact that during
compression, the unstable form 3 is transformed into a more
soluble form, which is observed with the X-ray diffraction by
an amorphization of form 3 resulting in the absence of its dif-
fraction peaks on the diffractogram (Fig. 7).
This hypothesis was also assumed by T.P Shakhtshneider in
his work dealing with the stabilization of metastable phases of
molecular crystals of Piroxicam and sulfathiazole under the ef-
fect of mechanical treatment (Shakhtshneider, 1997).
3.2.4. Dissolution proﬁles of tablets with extended release
The dissolution proﬁles of Piroxicam tablets (forms 1, 2 and 3)
containing 5% of metolose and represented in Fig. 12 show a
extended release of the active principle.As well, it is noted that according to these results and com-
pared to the dissolution proﬁles of pure polymorphs, the disso-
lution kinetics are in the following order: less extended for
form 3, then those of forms 2 and 1.
Indeed, the tablets formulated from polymorphs (forms 1
and 2) show, in addition to the extended release of the Pirox-
icam, similar dissolution proﬁles.
This is explained by the inﬂuence of metolose which, incor-
porated in the tablets at a rate of 5%, could possibly act twice.
- First protecting the polymorphic transition of the form 2
during compression; which is due to its elastic behavior.
- Then by modulating the release of the active principle (sus-
tained release).
3.2.5. Infra-red curves
In order to show the effect of hydroxypropylmethylcellulose
protection on Piroxicam polymorphic transition (form II) dur-
ing compression, we have completed our study by an infrared
analysis as described below:
In addition to conventional tablets and extended-release tab-
lets, formulated according to the previously mentioned compo-
sitions (Table 2), we have reformulated extended-release
Conventionnal 
tablet 3
Conventionnal 
tablet 2
Conventionnal 
tablet 1 
Form 3
Form 1
Form 2 
Figure 13 IR spectra of Piroxicam polymorphs and their conventional forms.
Role of hydroxypropylmethylcellulose (HPMC 4000) in the protection of the polymorphs of Piroxicam S1251tablets by incorporating only the matrix excipient HPMC 4000
(5%) to the active ingredient present in the formula at a rateequivalent to 4%, and completed with a ﬁller lactose
monohydrate.
Form 1
Form 2
Form 3
Extended -release 
tablet( F1) 
Extended -release 
tablet (F3)
Extended -release 
tablet( F2) 
Figure 14 IR spectra of Piroxicam polymorphs and their
extended forms.
Extended-release 
tablet (F1)+ HPMC 
Form 1 
Form 2
Form 3 
Extended-release 
tablet (F2) + HPMC
Extended-release 
tablet (F3)+ HPMC
Figure 15 IR spectra of Piroxicam polymorphs and their
extended forms with HPMC.
S1252 A. Merah et al.The IR spectra (Fig. 13) representing the infra-red poly-
morph proﬁles and the conventional forms show well the
change in the vibration bands corresponding to N–H function
located between 3337 cm1 and 3392 cm1.
The IR spectra (Fig. 14) representing the infra-red poly-
morph proﬁles and the extended forms show the widening of
the vibration band corresponding to the N–H function. Indeed
this widening appears well after having formulated extended
tablets of the different polymorphs with only HPMC 4000 at
a rate of 5% and having completed with monohydrated lactose
(Fig. 15).
The use of the infrared spectroscopy was, for a long time, a
means to show and explain the possible interactions between
active principle and excipient. In fact in our case the IR curves,
show well these interactions which appear as a peak at
3340 cm1 with a broad vibration band of N–H function of
Piroxicam which is quite visible with the use of the formulascontaining the HPMC 4000 as a single excipient of an exten-
tion effect.
4. Conclusion
The physico-chemical characterization of Piroxicam poly-
morphs (DRX), the follow-up of their evolution throughout
the formulation process of the extended release tablets with
the hydroxypropylmethylcellulose 4000 and the control of
the in vitro release of the active principle made it possible to
highlight the role of hydroxypropylmethylecellulose (HPMC
4000) in the protection of Piroxicam polymorphs.
In fact, the results revealed that hydroxypropylmethylcellu-
lose 4000 incorporated in a rate equivalent to 5% in the Pirox-
icam tablets, in addition to the extention effect; allows the
stabilization of form II during compression. This phenomenon
was clearly illustrated by the dissolution proﬁles.
Role of hydroxypropylmethylcellulose (HPMC 4000) in the protection of the polymorphs of Piroxicam S1253It will be thus possible to choose and suggest polymorph II,
in order to formulate a extended release tablet based on
hydroxypropylmethylcellulose (HPMC 4000): a matrix excipi-
ent known for its elastic behavior during compression.
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